HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

aripiprazole (Abilify)

Subscribe to New Research on aripiprazole

has both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity; structure given in first source; use associated with HYPERGLYCEMIA

Also Known As:

Abilify; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; Bristol-Myers Squibb brand of aripiprazole; OPC 14597; OPC-14597; Otsuka brand of aripiprazole

Networked: 1439 relevant articles (300 outcomes, 458 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Piperazines: 18
    - aripiprazole: 1439
- 2-Ring Heterocyclic Compounds
  - Quinolines: 92
    - Quinolones: 1190
      - aripiprazole: 1439

Experts

1.	McQuade, Robert D: 61 articles (07/2015 - 09/2002)
2.	Carson, William H: 47 articles (07/2015 - 09/2002)
3.	Marcus, Ronald N: 47 articles (12/2014 - 04/2006)
4.	Baker, Ross A: 32 articles (10/2015 - 12/2008)
5.	Forbes, Robert A: 28 articles (01/2014 - 11/2007)
6.	Pikalov, Andrei: 27 articles (06/2011 - 05/2007)
7.	Kane, John M: 26 articles (11/2015 - 09/2002)
8.	Eudicone, James M: 22 articles (01/2015 - 10/2007)
9.	Berman, Robert M: 22 articles (12/2014 - 12/2006)
10.	Sanchez, Raymond: 19 articles (07/2015 - 09/2005)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 09/01/2010 - "This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks." 08/01/2015 - "These results support aripiprazole lauroxil as an important new treatment option for schizophrenia. " 01/01/2015 - "Aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti-psychotic agent to be approved by the US Food and Drug Administration. " 02/01/2014 - "Three studies assessed the efficacy of aripiprazole on agitation symptoms in patients with schizophrenia and for which a dose of aripiprazole between 1 and 15mg showed significant efficacy compared to placebo. " 05/01/2004 - "In multiple clinical trials, aripiprazole was effective in significantly reducing symptomatology associated with schizophrenia-related disorders compared with placebo (P < 0.05). "
2.	Bipolar Disorder (Mania) 01/01/2015 - "Factors most predictive of endpoint efficacy for aripiprazole were judgment/impulsivity at day 4 and mania at week 1. Optimal factor score improvement for outcome prediction was approximately 40% to 50%. " 10/01/2007 - "Aripiprazole was effective in improving mania and ADHD symptoms, but neither JBD nor ADHD symptom remission was observed in most of the cases. " 09/01/2007 - "Aripiprazole was superior to placebo in reducing the severity of both mania and agitation in highly agitated patients with bipolar I disorder and showed significant antimanic activity in patients with low levels of agitation without increasing agitation. " 02/01/2014 - "Using trial data together with ancillary analyses, the European Medicines Agency concluded that aripiprazole 10 mg once daily for 12 weeks was effective in reducing symptoms of mania, but because of the high drop-out rate, efficacy over 30 weeks of treatment was not proven. " 02/01/2011 - "aripiprazole has proven to be an effective medication for the acute treatment of manic and mixed episodes, as well as for the prophylactic-maintenance phase of bipolar disorder in patients recovering from a manic/mixed episode. "
3.	Psychotic Disorders (Schizoaffective Disorder) 07/01/2009 - "During combined treatment with mean doses of 22.9 mg of aripiprazole for 9.7 weeks, we assessed a small yet statistically not significant improvement of the psychotic disorder, whereas a marked reduction of obsessions and significant improvements of compulsions could be observed. " 01/01/2010 - "Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report." 06/01/2010 - "The two cases presented raises attention not only to the success of aripiprazole prophylactic treatment, but also to several factors which in the future may aide the clinician in choosing the adequate pharmacological agent (gender, bipolar I disorder, psychotic mixed episodes, partial remission during interepisodes, effectiveness of low dose aripiprazole)." 09/01/2008 - "Aripiprazole should be considered as first line treatment in some patients affected by psychotic disorders visited in the emergency psychiatric setting." 05/01/2009 - "The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials."
4.	Major Depressive Disorder (Major Depressive Disorders) 02/01/2015 - "We describe the results of an open-label study designed to assess the effectiveness and tolerability of aripiprazole addition to an antidepressant in patients with major depressive disorder with postpartum onset who had not experienced significant clinical improvement following an adequate trial of an antidepressant. " 01/01/2015 - "There is evidence to suggest that aripiprazole is beneficial in major depressive disorder and BPD with depression. " 01/01/2011 - "Aripiprazole adjunctive to antidepressant treatment can have some beneficial effects on sexual functioning in patients with major depressive disorder who respond inadequately to standard antidepressant treatment; the benefits in women were specific to sexual interest and satisfaction and were independent of the improvement in depressive symptoms. " 01/01/2010 - "Adjunctive aripiprazole is beneficial for the treatment of patients with major depressive disorder but its effects on specific symptoms have not been reported. " 12/01/2011 - "To determine whether early symptom improvement with adjunctive aripiprazole in major depressive disorder (MDD) predicts overall symptom remission. "
5.	Movement Disorders (Movement Disorder) 03/01/2006 - "Marked improvement in chronic tardive dyskinesia after changing to aripiprazole." 01/01/2009 - "A further trial with aripiprazole, improved her tardive dyskinesia symptoms. " 06/01/2012 - "Switching to aripiprazole has been reported to improve tardive dyskinesia caused by other medications. " 01/01/2012 - "Two instances of improvement in tardive dyskinesia after administration of aripiprazole in a single patient." 06/01/2010 - "Case of tardive dystonia improved by aripiprazole."

Related Drugs and Biologics

1.	Risperidone (Risperdal Consta)
2.	olanzapine (Zyprexa)
3.	Antipsychotic Agents (Antipsychotics)
4.	quetiapine (Seroquel)
5.	Haloperidol (Haldol)
6.	ziprasidone (Geodon)
7.	Clozapine (Clozaril)
8.	Lithium
9.	Valproic Acid (Valproate, Semisodium)
10.	Dopamine (Intropin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Stents
4.	Intramuscular Injections
5.	Patient Readmission